The neuroprotective and neuronal rescue effects of (—)-deprenyl

  • K. Magyar
  • B. Szende
  • J. Lengyel
  • J. Tarczali
  • I. Szatmáry
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)


The pharmacological effects of (—)-deprenyl is multi-fold in its nature (dopamine sparing activity, neuroprotective and neuronal rescue effects), which cannot be explained solely by the irreversible MAO-B inhibitory action of the substance. Deprenyl slightly inhibits the re-uptake of noradrenaline and dopamine, but methylamphetamine, the metabolite of the inhibitor, by one order of magnitude is more potent in this respect, than the parent compound. Neither the metabolite nor (—)-deprenyl acts on the uptake of serotonin. The inhibitor has an intensive first pass metabolism after oral treatment. The in vivo pharmacokinetic studies with (—)-deprenyl, using the double labelled radioisotope technique (1.5mg/kg; orally) in rats revealed that the molar concentration of methylamphetamine can reach the level suitable to induce a significant inhibition of amine uptake. Deprenyl, but especially methylamphetamine pre-treatment can prevent the noradrenaline release induced by the noradrenergic neurotoxin DSP-4. The uptake inhibitory effect of (—)-deprenyl and the metabolites is reversible. After repeated administration of (—)-deprenyl (1.5mg/kg daily, for 8 days) sustained concentration of its metabolites was detected, compared to that of the acute studies. This can at least partly explain why (—)deprenyl should be administered daily to evoke therapeutic effects in Parkinson’s disease. Administration of (-)deprenyl in a low dose, following the toxic insult, can rescue the damaged neurones. The neuronal rescue effect of the drug was studied on M-1 human melanoma cells in tissue culture. The inhibitor reduced the apoptosis of serum-deprived M-1 cells, but the ( + )-isomer failed to exert this effect. The (±)-desmethyl-deprenyl almost lacks the property to inhibit apoptosis. For neuroprotection and neuronal rescue an optimal dose of (—)-deprenyl should be administered, because to reach a well balanced concentration of the metabolites in tissues is critical.


Human Melanoma Cell Corpus Striatum Neuronal Rescue Subacute Treatment Subacute Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ansari KS, Tatton WG, Yu PH, Kruck TPA (1993) Rescue of axotomised immature rat facial motoneurons by R(—)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042–4053PubMedGoogle Scholar
  2. Barber AJ, Paterson IA, Gelowitz DL, Voll CL (1993) Deprenyl protects rat hippocam-pal pyramidal cells from ischaemic insult. Soc Neurosci Abstr 19: 1646Google Scholar
  3. Berry MD, Juorio AV, Paterson IA (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 42: 375–391CrossRefPubMedGoogle Scholar
  4. Bey P, Fozard J, McDonald I, Palfreyman MG, Zreika M (1984) MDL 72145: a potent and selective inhibitor of MAO type B. Br J Pharmacol 81: 50PGoogle Scholar
  5. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Martin J (1985) Increased life expectancy resulting from addition of L-Deprenyl to MadoparR treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–128CrossRefPubMedGoogle Scholar
  6. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (—)-deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517–521CrossRefPubMedGoogle Scholar
  7. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26: 689–690CrossRefPubMedGoogle Scholar
  8. Dudley MW, Howard BD, Cho AK (1990) The interaction of the beta-haloethyl benzylamines, xylamine and DSP-4 with catecholaminergic neurones. Annu Rev Pharmacol Toxicol 30: 387–403CrossRefPubMedGoogle Scholar
  9. Finnegan KT, Skratt JS, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184: 119–126CrossRefPubMedGoogle Scholar
  10. Gibson CJ (1987) Inhibition of MAO-B, but not MAO-A blocks DSP-4 toxicity on central NE neurones. Eur J Pharmacol 141: 135–138CrossRefPubMedGoogle Scholar
  11. Glover V, Gibb C, Sandler M (1986) The role of MAO in MPTP toxicity — a review. J Neural Transm [Suppl 20]: 65–76Google Scholar
  12. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M, et al (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126: 93–99Google Scholar
  13. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297CrossRefPubMedGoogle Scholar
  14. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (—)-deprenyl. Mech Aging Dev 46: 237–262CrossRefPubMedGoogle Scholar
  15. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408PubMedGoogle Scholar
  16. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethyl-propinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154–164PubMedGoogle Scholar
  17. Ladányi A, Timár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46: 456–461CrossRefPubMedGoogle Scholar
  18. Lai CT, Zuo DM, Yu PH (1994) Is brain superoxide dismutase activity increased following chronic treatment with L-deprenyl? J Neural Transm 41: 221–229Google Scholar
  19. Langston JW (1990) (—)-deprenyl as neuroprotective therapy in Parkinson’s disease: concepts and controversies. Neurology [Suppl 3] 40: 61–66PubMedGoogle Scholar
  20. Magyar K (1992) Pharmacology of monoamine oxidase type B inhibitors. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhäuser, Basel, pp 125–143Google Scholar
  21. Magyar K (1994) Behaviour of (—)-deprenyl and its analogues. J Neural Transm 41:167–175Google Scholar
  22. Magyar K (1996a) The role of the metabolism of (—)-deprenyl in neuroprotection. J Neurochem 66[Suppl 2]: S20 DGoogle Scholar
  23. Magyar K (1996b) The role of the metabolism of (—)-deprenyl in neuroprotection. J Neurochem (in press)Google Scholar
  24. Magyar K, Szüts T (1982) The fate of (—)-deprenyl in the body. Preclinical studies. In: Proceedings of the International Symposium on (—)-deprenyl, Jumex, Szombathely, Hungary, pp 25–31Google Scholar
  25. Magyar K, Tóthfalusi L (1984) Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 36: 373–384CrossRefPubMedGoogle Scholar
  26. Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Hung 32: 377–387Google Scholar
  27. Magyar K, Lengyel J, Szatmári I, Gaál J (1995) The distribution of orally administered (—)-deprenyl-propargyl-14C and (—)-deprenyl-phenyl-3H in rat brain. Prog Brain Res 106: 143–153CrossRefPubMedGoogle Scholar
  28. Magyar K, Szende B, Lengyel J, Tekes K (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (—)-deprenyl research. J Neural Transm 48: 29–43Google Scholar
  29. Nagatsu T, Hirata Y (1987) Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpiridinium ion (MPP+) and the structurally related compounds in vitro and in vivo. Eur Neurol 26[Suppl 1]: 11CrossRefPubMedGoogle Scholar
  30. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544CrossRefPubMedGoogle Scholar
  31. Ross SB, Renyi AL (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of adrenaline. J Pharm Pharmacol 28: 458–459CrossRefPubMedGoogle Scholar
  32. Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B (1980) Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry 43: 1016–1021CrossRefPubMedGoogle Scholar
  33. Strolin-Benedetti M, Dostert P (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38: 555–561CrossRefPubMedGoogle Scholar
  34. Szökö É, Magyar K (1995) Chiral separation of deprenyl and its major metabolites using cyclodextrin-modified capillary zone electrophoresis. J Chromatogr A 709: 157–162CrossRefGoogle Scholar
  35. Szökö É, Magyar K (1996) Enantiomer identification of the major metabolites of (—)-deprenyl in rat urine by capillary electrophoresis. Int J Pharm Adv 1: 320–328Google Scholar
  36. Tatton WG, Greenwood CE (1991) Rescue of dying neurones: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666–672CrossRefPubMedGoogle Scholar
  37. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994) (—)-deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63: 1572–1575CrossRefPubMedGoogle Scholar
  38. Tekes K, Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 40:653–658PubMedGoogle Scholar
  39. Tipton KF (1980) Kinetics and enzyme inhibition studies. In: Sandler M (ed) Enzyme inhibitors and drugs. McMillen, London, pp 1–23Google Scholar
  40. Wyllie AH, Kerr JFR, Currie AR (1986) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306CrossRefGoogle Scholar
  41. Yu PH, Davis BA, Fang J, Boulton AA (1994) Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4 induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63: 1820–1828CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • K. Magyar
    • 1
    • 5
  • B. Szende
    • 2
  • J. Lengyel
    • 3
  • J. Tarczali
    • 1
  • I. Szatmáry
    • 4
  1. 1.Departments of PharmacodynamicsSemmelweis University of MedicineBudapestHungary
  2. 2.Departments of Pathology and Experimental Cancer ResearchSemmelweis University of MedicineBudapestHungary
  3. 3.Departments of Central Isotope LaboratorySemmelweis University of MedicineBudapestHungary
  4. 4.Chinoin Pharmaceutical WorksBudapestHungary
  5. 5.Department of PharmacodynamicsSemmelweis University of MedicineBudapestHungary

Personalised recommendations